UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Radiofrequency ablation and cryoablation for renal cell carcinoma

Authors
Andrew Hines-Peralta, MD
S Nahum Goldberg, MD
Section Editors
Michael B Atkins, MD
Jerome P Richie, MD, FACS
Deputy Editor
Michael E Ross, MD

INTRODUCTION

There are over 50,000 new cases of renal cell carcinoma (RCC) diagnosed each year in the United States, and the incidence has been increasing over time. (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma".)

The average size of these RCCs at presentation is decreasing, and more patients are presenting with small, localized lesions. In addition, there is an increasing awareness of the importance of preserving renal function, if this can be accomplished without compromising the oncologic outcome. (See "Diagnostic approach, differential diagnosis, and treatment of a small renal mass" and "Definitive surgical management of renal cell carcinoma", section on 'Partial nephrectomy'.)

Sharply delineated areas of very high or low temperature can be created in a minimally invasive fashion with either radiofrequency ablation (RFA), cryoablation, or microwave ablation. These temperature extremes are used to produce tumor cell death. Emerging technologies, such as non-thermal irreversible electroporation (IRE) can also induce cell death and are in early clinical trials [1]. These minimally invasive technologies are rapidly gaining acceptance in selected patients as alternatives to surgery for many tumors, including RCC.

The increasing acceptance of RFA and cryoablation for kidney tumors is based upon favorable outcomes in initial studies, a low incidence of serious complications, less immediate morbidity than with surgery, lower cost, and the ability to treat patients in the outpatient setting. Optimal application of these ablative techniques requires interventional radiologists and urologists who are experienced and skilled in the application of the technology.

The potential benefits of these ablative techniques must be balanced against limited long-term, comparative efficacy data. In addition, multiple treatment sessions may be required because of difficulties in monitoring the extent of ablation, particularly for tumors greater than 4 cm in diameter. Furthermore, these ablative techniques may not be appropriate for large lesions or tumors near the renal hilum.

               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Jul 01 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Wendler JJ, Porsch M, Nitschke S, et al. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial). Contemp Clin Trials 2015; 43:10.
  2. Onishi T, Nishikawa K, Hasegawa Y, et al. Assessment of health-related quality of life after radiofrequency ablation or laparoscopic surgery for small renal cell carcinoma: a prospective study with medical outcomes Study 36-Item Health Survey (SF-36). Jpn J Clin Oncol 2007; 37:750.
  3. Pandharipande PV, Gervais DA, Mueller PR, et al. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology 2008; 248:169.
  4. Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. J Vasc Interv Radiol 2001; 12:1021.
  5. Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011; 258:351.
  6. Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 2007; 178:379.
  7. Gervais DA, McGovern FJ, Arellano RS, et al. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005; 185:64.
  8. Gervais DA, Arellano RS, McGovern FJ, et al. Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005; 185:72.
  9. Tracy CR, Raman JD, Donnally C, et al. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 2010; 116:3135.
  10. Zagoria RJ, Traver MA, Werle DM, et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007; 189:429.
  11. Breen DJ, Rutherford EE, Stedman B, et al. Management of renal tumors by image-guided radiofrequency ablation: experience in 105 tumors. Cardiovasc Intervent Radiol 2007; 30:936.
  12. Levinson AW, Su LM, Agarwal D, et al. Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 2008; 180:499.
  13. Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. BJU Int 2007; 99:1265.
  14. Atwell TD, Callstrom MR, Farrell MA, et al. Percutaneous renal cryoablation: local control at mean 26 months of followup. J Urol 2010; 184:1291.
  15. Atwell TD, Farrell MA, Callstrom MR, et al. Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome. AJR Am J Roentgenol 2007; 188:1195.
  16. Gervais DA. Cryoablation versus radiofrequency ablation for renal tumor ablation: time to reassess? J Vasc Interv Radiol 2013; 24:1135.
  17. Moreland AJ, Ziemlewicz TJ, Best SL, et al. High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation. J Endourol 2014; 28:1046.
  18. Finley DS, Beck S, Box G, et al. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol 2008; 180:492.
  19. Zargar H, Atwell TD, Cadeddu JA, et al. Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. Eur Urol 2016; 69:116.
  20. Liang P, Wang Y, Zhang D, et al. Ultrasound guided percutaneous microwave ablation for small renal cancer: initial experience. J Urol 2008; 180:844.
  21. Yu J, Liang P, Yu XL, et al. US-guided percutaneous microwave ablation of renal cell carcinoma: intermediate-term results. Radiology 2012; 263:900.
  22. Guan W, Bai J, Liu J, et al. Microwave ablation versus partial nephrectomy for small renal tumors: intermediate-term results. J Surg Oncol 2012; 106:316.
  23. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? Diagn Interv Radiol 2013; 19:501.
  24. Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation ablation: is all the damage nonthermal? Radiology 2013; 266:462.
  25. Cannon R, Ellis S, Hayes D, et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107:544.
  26. Olweny EO, Kapur P, Tan YK, et al. Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology 2013; 81:679.
  27. Allen BC, Remer EM. Percutaneous cryoablation of renal tumors: patient selection, technique, and postprocedural imaging. Radiographics 2010; 30:887.
  28. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer 2008; 113:2671.
  29. Psutka SP, Feldman AS, McDougal WS, et al. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 2013; 63:486.
  30. Tanagho YS, Bhayani SB, Kim EH, Figenshau RS. Renal cryoablation versus robot-assisted partial nephrectomy: Washington University long-term experience. J Endourol 2013; 27:1477.
  31. Caputo PA, Ramirez D, Zargar H, et al. Laparoscopic Cryoablation for Renal Cell Carcinoma: 100-Month Oncologic Outcomes. J Urol 2015; 194:892.
  32. Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015; 67:252.
  33. Klatte T, Shariat SF, Remzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. J Urol 2014; 191:1209.
  34. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol 2014; 37:427.
  35. Wah TM, Arellano RS, Gervais DA, et al. Image-guided percutaneous radiofrequency ablation and incidence of post-radiofrequency ablation syndrome: prospective survey. Radiology 2005; 237:1097.
  36. Hui GC, Tuncali K, Tatli S, et al. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 2008; 19:1311.
  37. Kim EH, Tanagho YS, Saad NE, et al. Comparison of laparoscopic and percutaneous cryoablation for treatment of renal masses. Urology 2014; 83:1081.
  38. Wah TM, Irving HC, Gregory W, et al. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014; 113:416.